Abstract: Objectives To investigate the efficacy of domestic pegylated interferonα-2b （peg-IFN-α-2b） in treatment of patients with serum HBeAg positive chronic hepatitis B（CHB）. Methods 500 patients with serum HBeAg positive CHB were recruited in this study between January 2015 and December 2017,and 150 patients in group A were treated by domestic peg-IFN-α-2b,and 350 patients in group B received peg-IFN-α-2a. The regimen lasted for 24 to 48 weeks,and all patients with CHB were followed-up for 24 weeks. Results At presentation,serum HBV DNA loads,serum alanine aminotransferase（ALT） level,body mass index,serum HBeAg and HBsAg levels in group A were （6.1±0.7） lg cps/ml,（81.1±29.8） U/L,（22.1±2.9）,（3.1±0.6） lg s/co and （4.4±0.6） IU/ml,without significantly different as compared to（6.2±0.67） lg cps/ml,（80.7±27.9） u/l,（21.9±2.9）,（3.1±0.1） lg s/co and （4.4±0.5） IU/ml in group B（P>0.05）;at the end of 24 week follow-up,serum ALT normalization rate and serum HBV DNA loss in group A were 64.0% and 60.0%,also no significantly different as compared to 66.9% and 62.9% in group B（P>0.05）;the side effects during the antiviral treatment in the two groups were not significantly different（P>0.05）. Conclusion The application of domestic peg-IFN-α-2b in treatment of patients with serum HBeAg-positive CHB might get the same viralogic and biochemical responses,and the regimen is safe and cheap,which warrants further clinical investigation.

Key words: Hepatitis B, Serum HBeAg positive, Polyethylene glycol interferon α-2b;, Efficacy